eMedicine Specialties > Obstetrics and Gynecology > Gynecologic Oncology
Malignant Lesions of the Fallopian Tube and Broad Ligament: Differential Diagnoses & Workup
Updated: Oct 9, 2008
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
Differential Diagnoses
Other Problems to Be Considered
Benign fallopian tube disease salpingitis (eg, tuberculosis salpingitis)
Benign ovarian disease
Ovarian tumor of low malignant potential
Malignant epithelial ovarian tumors
Broad ligament tumors
Workup
Laboratory Studies
- Investigations usually are for postmenopausal bleeding and include the following:
- Papanicolaou smear test, showing malignant glandular cells
- Endometrial biopsy
- The cancer antigen 125 (CA-125) tumor marker assay is performed for follow-up study as a marker of response to therapy.
Imaging Studies
- Hysterosalpingogram can help detect intraluminal growth.
- Color Doppler can help detect arteriovenous shunts, microaneurysms, tumoral lakes, vascular blind ends, dichotomous branching, neovascularization, and low resistance indices.
- Three-dimensional ultrasound can help detect papillary protrusions, pseudoseptae, tumoral lakes, microaneurysms, and arteriovenous shunting.
- Ultrasound helps detect an adnexal mass, especially a solid mass corresponding with the expected location of the fallopian tubes in association with normal ovaries or as a sausage-shaped cystic mass with papillary projections.
Histologic Findings
Type of carcinomas found include serous carcinoma (50%), endometrioid carcinoma (25%), transitional cell carcinoma (11.7%), undifferentiated carcinoma (7.8%), mixed carcinoma (3.9%), and clear cell carcinoma (1.9%).
Immunohistochemistry: Glucose transporter (GLUT1) immunostaining of fallopian tube adenocarcinoma was stronger and more extensive than staining of benign tubal epithelium. GLUT1 positivity is observed in regions most distal from stromal capillaries, suggesting hypoxia-driven GLUT1 induction. On average, GLUT1 staining in primary fallopian tube cancer was less extensive than in primary ovarian adenocarcinomas.2
Staging
Although the fallopian tubes are derived from the same embryonic structure as the uterus, histologically and clinically, malignant lesions of the fallopian tubes behave like ovarian tumors. Unlike ovarian tumors, 50% of fallopian tube tumors are stage I and II, whereas more than 50% of ovarian malignancies are usually in stage III and IV. Fallopian tube carcinomas have a predilection for metastasis to retroperitoneal lymph nodes in contrast to intraperitoneal spread of ovarian carcinomas.
- International Federation of Gynecology and Obstetrics (FIGO) fallopian tube cancer staging is as follows:
- Stage 0 - Carcinoma in situ (limited to tubal mucosa)
- Stage I - Growth limited to the fallopian tubes
- Stage Ia - Growth limited to 1 tube, with extension into the submucosa and/or muscularis but not penetrating the serosal surface; no ascites
- Stage Ib - Growth limited to both tubes with extension into the submucosa and/or muscularis but not penetrating the serosal surface; no ascites
- Stage Ic - Tumor stage 1a or 1b but with tumor extension through or onto the tubal serosa, or with ascites present containing malignant cells, or with positive peritoneal washings
- Stage II - Growth involving 1 or both fallopian tubes with pelvic extension
- Stage IIa - Extension and/or metastasis to the uterus and/or ovaries
- Stage IIb - Extension to other pelvic tissues
- Stage IIc - Tumor stage IIa or IIb, with ascites present containing malignant cells, or with positive peritoneal washings
- Stage III - Tumor involving 1 or both fallopian tubes, with peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal nodes; superficial liver metastasis equals stage III; tumor appears limited to true pelvis but has histologically proven malignant extension to the small bowel or omentum
- Stage IIIa - Tumor grossly limited to the true pelvis, with negative nodes but with histologically confirmed microscopic seeding or abdominal peritoneal surfaces
- Stage IIIb - Tumor involving 1 or both fallopian tubes, with histologically confirmed implants on abdominal peritoneal surfaces, none exceeding 2 cm in diameter; lymph node findings negative
- Stage IIIc - Abdominal implants larger than 2 cm in diameter and/or positive retroperitoneal or inguinal nodes
- Stage IV - Growth involving 1 or both fallopian tubes, with distant metastases; if pleural effusion is present, positive cytology results necessary to be stage IV; parenchymal liver metastases equal stage IV
- Staging for fallopian tube carcinoma is via the surgical pathological system. Operative findings designating stage are determined before tumor debulking.
- Modified FIGO staging for fallopian tube carcinoma is as follows:
- Stage 0 - Carcinoma in situ (limited to tubal epithelium)
- Stage I - Growth limited to tube
- Stage IA - Growth limited to 1 fallopian tube, without extension through or onto serosa, ascites containing malignant cells, or positive peritoneal washings
- Stage IA to 0b - Growth limited to 1 fallopian tube, with no extension into lamina propria
- Stage IA to 1b - Growth limited to 1 fallopian tube, with extension into lamina propria but no extension into muscularis
- Stage IA to 2b - Growth limited to 1 fallopian tube, with extension into muscularis
- Stage IB - Growth limited to both fallopian tubes, without extension through or onto serosa, ascites containing malignant cells, or positive peritoneal washings
- Stage IB to 0b - Growth limited to both fallopian tubes, with no extension into lamina propria
- Stage IB to 1b - Growth limited to both fallopian tubes, with extension into lamina propria, but not extension into muscularis
- Stage IB to 2b - Growth limited to both fallopian tubes, with extension into muscularis
- Stage IC - Tumor either stage IA or IB, but with extension through or onto tubal serosa, with ascites containing malignant cells, or with positive peritoneal washings
- Stage I(F) - Tumor limited to fimbriated end of fallopian tube(s), without invasion of tubal wall
- Stage II - Tumor involving 1 or both fallopian tubes, with pelvic extension
- Stage IIA - Extension and/or metastasis to uterus and/or ovaries
- Stage IIB - Extension to other pelvic tissues
- Stage IIC - Tumor either stage IIA or IIB, with ascites containing malignant cells or with positive peritoneal washings
- Stage III - Tumor involving 1 or both fallopian tubes, with peritoneal implants outside pelvis, including superficial liver metastasis, and/or positive retroperitoneal or inguinal nodes; tumor limited to pelvis except for histologically proven extension to small bowel or omentum
- Stage IIIA - Tumor grossly limited to pelvis, with negative nodes but with histologically confirmed microscopic seeding of abdominal peritoneal surfaces
- Stage IIIB - Tumor involves 1 or both fallopian tubes, with grossly visible histologically confirmed implants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter; lymph node findings negative
- Stage IIIC - Abdominal implants larger than 2 cm in diameter and/or positive retroperitoneal or inguinal nodes
- Stage IV - Growth involving 1 or both fallopian tubes, with distant metastases, including parenchymal liver metastases; if pleural effusion present, fluid must be positive cytologically for malignant cells
- Modification in terminology - Modifications to accommodate subsets of tumor that otherwise cannot be assigned a stage or to distinguish among subsets that may differ in their associated prognosis
More on Malignant Lesions of the Fallopian Tube and Broad Ligament |
| Overview: Malignant Lesions of the Fallopian Tube and Broad Ligament |
 Differential Diagnoses & Workup: Malignant Lesions of the Fallopian Tube and Broad Ligament |
| Treatment & Medication: Malignant Lesions of the Fallopian Tube and Broad Ligament |
| Follow-up: Malignant Lesions of the Fallopian Tube and Broad Ligament |
| References |
| « Previous Page | Next Page » |
References
Orthmann EG. Primareskarzinom in Einertuberkulosen. Ztschr Geburtsh Gynaek. 1888;15:212.
Kalir T, Rahaman J, Hagopian G, Demopoulos R, Cohen C, Burstein DE. Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med. May 2005;129(5):651-4. [Medline].
Alvarado-Cabrero I, Young RH, Vamvakas EC. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol. Mar 1999;72(3):367-79. [Medline].
Aslani M, Scully RE. Primary carcinoma of the broad ligament. Report of four cases and review of the literature. Cancer. Oct 1 1989;64(7):1540-5. [Medline].
Ben-Hur H, Dgani R, Ben-Arie A. Diagnostic dilemmas and current therapy of Fallopian tube cancer. Eur J Gynaecol Oncol. 1999;20(2):108-9. [Medline].
Berek J, Hacker N, eds. Practical Gynecologic Oncology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:546.
Danforth DN, Scott JR. Diseases of the ovary and fallopian tubes. In: Danforth DN, Scott JR, Di Saia PJ, Hammond CB, Spellacy WN, eds. Danforth's Obstetrics & Gynecology. 8th ed. Philadelphia, Pa: Lippincott Raven; 1999:889.
Dieste MC, Lynch GR, Gordon A. Malignant fibrous histiocytoma of the broad ligament: a case report and literature review. Gynecol Oncol. Oct 1987;28(2):225-9. [Medline].
Disaia PJ, Creasman WT. Fallopian tube cancer. In: Creasman WT, Doherty M, Disaia PJ, Dinh TV, Hannigan EV, eds. Clinical Gynecologic Oncology. 5th ed. St. Louis, Mo: Mosby-Year Book; 1997:375-80.
Dunton CJ, Neufeld J. Complete response to topotecan of recurrent fallopian tube carcinoma. Gynecol Oncol. Jan 2000;76(1):128-9. [Medline].
Fedele L, Cittadini E, Bortolozzi G. Successful in vitro fertilization and embryo transfer after limited surgical treatment for tubal adenocarcinoma. Cancer. Oct 1 1989;64(7):1546-7. [Medline].
Kurjak A, Kupesic S, Jacobs I. Preoperative diagnosis of the primary fallopian tube carcinoma by three- dimensional static and power Doppler sonography. Ultrasound Obstet Gynecol. Mar 2000;15(3):246-51. [Medline].
Latner AL, Turner GA. Effect of aprotinin on immunological resistance in tumour-bearing animals. Br J Cancer. May 1976;33(5):535-8. [Medline].
Loverro G, Cormio G, Renzulli G. Serous papillary cystadenoma of borderline malignancy of the broad ligament. Eur J Obstet Gynecol Reprod Biol. Aug 1997;74(2):211-3. [Medline].
Navani SS, Alvarado-Cabrero I, Young RH. Endometrioid carcinoma of the fallopian tube: a clinicopathologic analysis of 26 cases. Gynecol Oncol. Dec 1996;63(3):371-8. [Medline].
Ricci JV. One Hundred Years of Gynecology. Philadelphia, Pa: Blackiston; 1945.
Rose PG, Shrigley R, Wiesner GL. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol. May 2000;77(2):319-20. [Medline].
Rosen AC, Ausch C, Hafner E. A 15-year overview of management and prognosis in primary fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Eur J Cancer. Oct 1998;34(11):1725-9. [Medline].
Rosen AC, Ausch C, Klein M. p53 expression in fallopian tube carcinomas. Cancer Lett. Aug 1 2000;156(1):1-7. [Medline].
Further Reading
Keywords
malignant lesions of the fallopian tube and broad ligament, fallopian tube malignancy, fallopian tube cancer, fallopian tube carcinoma, broad ligament malignancy, broad ligament cancer, gynecologic cancer, dysplasia, carcinoma in situ, CIS, endometriosis
